Substantial evidence suggests that the novel glucose-lowering agents, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), reduce the incidence of significant cardiovascular events in those who have type 2 diabetes [4-6]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.